First quarter earnings reports from Johnson & Johnson and Abbott Laboratories provided some surprising insights into the ...

After more than three years of discussion, the World Health Organization’s Intergovernmental Negotiating Body (INB) has ...

Johnson & Johnson’s Medtech division reported the completion of the first cases in the clinical trial for the Ottava robotic ...

Nipah virus, which circulates in fruit bats and other animals primarily in Asia and the South Pacific, causes severe ...

Biopharma dealmaking surged in the first quarter of 2025, totaling $66.86 billion, well ahead of the $44.16 billion recorded ...

The Trump administration sent several signals about the imposition of tariffs on semiconductors – a vital component for many devices. While imaging systems sell infrequently and may not suffer from a ...

The U.S. National Security Commission on Emerging Biotechnology (NSCEB) is urging Congress to reinvest in American biotechnology because “the U.S. is dangerously close to falling behind China,” ...

Earendil Labs will collaborate with Sanofi SA in a $1.8 billion license deal. Earendil, which specializes in artificial intelligence-based R&D for biologics, is getting $125 million up front and $50 ...

The U.S. Centers for Medicare & Medicaid Services decided to peel back a series of local coverage determinations for skin substitute grafts that provoked a vigorous response from stakeholders.

Genes associated with lysosomal dysfunction increase the risk of Parkinson’s disease (PD), according to a study led by ...

Days after Pfizer Inc. pulled the plug on its oral GLP-1 candidate danuglipron, Eli Lilly and Co. aired positive top-line data from the phase III trial called Achieve-1 testing orforglipron vs.

Newco Brink Therapeutics SAS is poised to work on the next chapter in genome editing after raising €3.5 million (US$4 million) in seed funding to discover and develop programmable recombinase enzymes.